In Vitro Susceptibility of Colistin Against Multidrug Resistant Klebsiella Pneumoniae Clinical Isolates

Objectives: To determine in-vitro efficacy of colistin against resistant Klebsiella Pneumoniae clinical isolates. Study Design: Cross-sectional study. Place and Duration of Study: Microbiology Department of Pathology Lab, Armed Forces Institute of Cardiology & National Institute of Heart Diseases, Rawalpindi, Pakistan, from Jan 2021 to Dec 2021. Methodology: This cross-sectional study was carried out at the microbiology department of pathology lab, Armed Forces institute of Cardiology & National Institute of Heart Diseases, Rawalpindi through Jan 2021 to Dec 2021. Sampling was done by nonprobability consecutive technique. Antimicrobial susceptibility testing was done for all clinical isolates of KP. Results: A total of 3066 culture and sensitivity requests were received, out of these 663(21.6%) specimens revealed growth of different microorganisms. Amongst 663 culture positive isolates, 150(22.6 %) were identified as KP. Antibiotic susceptibility of KP showed >90% isolates resistant to 3rd & 4th generation cephalosporins, cotrimoxazole, ampicillin+salbactum and coamoxiclav. Aminoglycosides, quinolones, meropenem, aztreonam and tazobactum+pipracillin were found resistant in >80% isolates and doxycycline and imipenem in >70% isolates. Resistance to minocycline was 58%, chloramphenicol 40.7% and Tigecycline 38.7%. The least resistance was noted in Colistin 16%. Conclusion: A very high antimicrobial resistance was observed in KP isolates against penicillins, cephalosporins, ampicillin beta lactamase inhibitor combinations, quinolones, aminoglycosides, carbapenems and cotrimoxazole. Comparatively tigecyclines and chloramphenicol were found to be less resistant than other antimicrobials to manage MDR and XDR cases. Colistin has excellent efficacy against MDR and XDR KP isolates.

[1]  M. Thaller,et al.  Fighting MDR-Klebsiella pneumoniae Infections by a Combined Host- and Pathogen-Directed Therapeutic Approach , 2022, Frontiers in Immunology.

[2]  F. Shahcheraghi,et al.  Comparative genome analysis of colistin-resistant OXA-48-producing Klebsiellapneumoniae clinical strains isolated from two Iranian hospitals , 2021, Annals of Clinical Microbiology and Antimicrobials.

[3]  S. Acharya,et al.  Molecular Epidemiological Surveillance of CTX-M-15-producing Klebsiella pneumoniae from the patients of a teaching hospital in Sindh, Pakistan. , 2021, F1000Research.

[4]  K. Prasad,et al.  Genetic Characterisation of Colistin Resistant Klebsiella pneumoniae Clinical Isolates From North India , 2021, Frontiers in Cellular and Infection Microbiology.

[5]  M. Khurshid,et al.  In-Vitro Assessment Of The Therapeutic Potential Of Polymyxins And Tigecycline Against Multidrugresistant Acinetobacter Isolates From Infected Wounds. , 2020, Journal of Ayub Medical College, Abbottabad : JAMC.

[6]  I. Ghout,et al.  Efficacy of generic meropenem products in combination with colistin in carbapenemase-producing Klebsiella pneumoniae experimental osteomyelitis. , 2020, International journal of antimicrobial agents.

[7]  N. French,et al.  Effectiveness and Safety of High Dose Tigecycline for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis , 2020, Advances in Therapy.

[8]  Yongjun Wu,et al.  Klebsiella pneumoniae: an increasing threat to public health , 2020, Annals of Clinical Microbiology and Antimicrobials.

[9]  Y. Doi,et al.  Colistin and its role in the Era of antibiotic resistance: an extended review (2000–2019) , 2020, Emerging microbes & infections.

[10]  M. Al-agamy,et al.  Emergence of colistin resistance in multidrug-resistant Klebsiella pneumoniae and Escherichia coli strains isolated from cancer patients , 2019, Annals of Clinical Microbiology and Antimicrobials.

[11]  P. Nordmann,et al.  Efficacy of colistin alone and in various combinations for the treatment of experimental osteomyelitis due to carbapenemase-producing Klebsiella pneumoniae. , 2019, The Journal of antimicrobial chemotherapy.

[12]  D. Nicolau,et al.  Evaluation of Plazomicin, Tigecycline, and Meropenem Pharmacodynamic Exposure against Carbapenem-Resistant Enterobacteriaceae in Patients with Bloodstream Infection or Hospital-Acquired/Ventilator-Associated Pneumonia from the CARE Study (ACHN-490-007) , 2019, Infectious Diseases and Therapy.

[13]  M. Bassetti,et al.  Multidrug-resistant Klebsiella pneumoniae: challenges for treatment, prevention and infection control , 2018, Expert review of anti-infective therapy.

[14]  Yang Wang,et al.  Emergence of a novel mobile colistin resistance gene, mcr-8, in NDM-producing Klebsiella pneumoniae , 2018, Emerging Microbes & Infections.

[15]  Jacqueline A. Keane,et al.  Phylogenetic Analysis of Klebsiella pneumoniae from Hospitalized Children, Pakistan , 2017, Emerging infectious diseases.

[16]  P. Srinivas,et al.  Polymyxin Resistance in Gram-negative Pathogens , 2017, Current Infectious Disease Reports.

[17]  P. Plésiat,et al.  Resistance to polymyxins in Gram-negative organisms. , 2017, International journal of antimicrobial agents.

[18]  E. Percivalle,et al.  Colistin inhibits E. coli O157:H7 Shiga-like toxin release, binds endotoxins and protects Vero cells. , 2016, The new microbiologica.

[19]  G. Daikos,et al.  Klebsiella pneumoniae: Virulence, Biofilm and Antimicrobial Resistance. , 2017 .